• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ICU Medical Introduces Its New Category of Infusion Devices With FDA Clearances of Plum Solo™ and Plum Duo™ Precision IV Pumps

    4/7/25 8:00:00 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care
    Get the next $ICUI alert in real time by email

    New devices address infusion delivery variability and expand the ICU Medical IV Performance Platform.

    SAN CLEMENTE, Calif., April 7, 2025 /PRNewswire/ -- ICU Medical Inc. (NASDAQ:ICUI), a worldwide leader in the development, manufacture and sale of innovative medical devices, has announced 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Plum Solo™ precision IV pump, a single-channel complement to the dual-channel Plum Duo™. ICU Medical also received 510(k) clearance for updated versions of the Plum Duo precision IV pump and LifeShield™ infusion safety software, completing the initial launch of the ICU Medical IV Performance Platform. With these FDA clearances, ICU Medical is introducing its new category of precision IV pumps and expanding the ICU Medical IV Performance Platform.

    With these FDA clearances, ICU Medical is introducing its new category of precision IV pumps and expanding the ICU Medical IV Performance Platform.

    Unlike traditional pumps that rely on specific setups and conditions for accurate delivery, precision IV pumps are designed to address delivery variability while supporting the increasing need for accurate data in modern patient care. Built on the unique cassette technology in the Best in KLAS award-winning Plum 360™, the Plum Solo and Plum Duo precision IV pumps deliver ±3% accuracy in real-world conditions and eliminate the infusion inconsistencies found in traditional pumps, providing clinicians with predictable performance and reliable infusion documentation.

    "Precision IV pumps represent a critical step forward for infusion therapy," said Chad Jansen, corporate vice president and general manager of ICU Medical Infusion Systems. "With the Plum Solo and Plum Duo, we're introducing more than just a new device category—we're setting a new standard. Healthcare teams can now trust not only the delivery of their medications but also the infusion data that supports their decisions, knowing it reflects what patients actually receive."

    The Plum Solo expands the capabilities of the IV Performance Platform by offering a single-channel pump designed to work alongside the dual-channel Plum Duo—recently recognized in a KLAS Emerging Insights Report with emerging data showing an A+ rating for new technology, likely to recommend, and money's worth.

    Together, Plum Solo and Plum Duo provide healthcare systems with the flexibility to choose the right configuration for their infusion needs, optimizing device footprint without compromising performance or safety. Both devices are compatible with whole blood and blood products and deliver consistent ±3% accuracy while eliminating variability from external factors such as infusion setup, temperature, or hospital elevation. Benefits of the IV Performance Platform include:

    • Precise Delivery: Unique pumping mechanism allowing for accurate and precise medication delivery—including whole blood and blood products—with both Plum Solo and Plum Duo pumps, no matter where the pump or the infusion bag is placed.
    • Simplified User Experience: Full-color touchscreens (7-inch on Plum Solo, 10-inch on Plum Duo) deliver intuitive programming with near real-time safety feedback for faster workflows and reduced cognitive load.
    • Streamlined Medication Management: Simplified drug library and firmware deployment, managed from a central location anytime, anywhere, to help ensure devices are consistently updated and pumps are on the most current software version.
    • Full IV-EHR Interoperability: Built on ICU Medical's 16 years of industry-leading experience, LifeShield software connectivity and integration can support better decision-making and more coordinated care across healthcare systems.
    • Future Ready: The LifeShield enterprise ecosystem will provide a single, harmonized IT platform for ICU Medical's road map of delivering best-of-breed devices for every infusion modality.

    "We are proud of this milestone, but this is just the next step in creating the most comprehensive, precise, and technologically advanced infusion platform," Jansen said. "This milestone delivers on our promised roadmap with 5 products receiving FDA 510(k) clearance in the past 18 months. We look forward to bringing our next-generation MedfusionTM syringe pump and CADDTM pain and ambulatory pump products to the LifeShield platform. This is the future of infusion therapy, and we're proud to be leading the way."

    Media Contact:

    Harrison Richards

    ICU Medical, Inc.

    949-366-4261    

    [email protected] 

    ICU Medical, Inc. Logo. (PRNewsFoto/ICU Medical, Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/icu-medical-introduces-its-new-category-of-infusion-devices-with-fda-clearances-of-plum-solo-and-plum-duo-precision-iv-pumps-302421156.html

    SOURCE ICU Medical, Inc.

    Get the next $ICUI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ICUI

    DatePrice TargetRatingAnalyst
    8/15/2025$145.00Overweight
    Piper Sandler
    3/12/2025$205.00 → $197.00Outperform → Strong Buy
    Raymond James
    12/11/2024$200.00Hold → Buy
    Jefferies
    10/14/2024$183.00Hold
    Jefferies
    6/21/2024Hold
    Needham
    6/17/2024$135.00Mkt Perform → Outperform
    Raymond James
    11/8/2022Outperform → Mkt Perform
    Raymond James
    2/28/2022$286.00 → $265.00Outperform
    Raymond James
    More analyst ratings

    $ICUI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman and CEO Jain Vivek bought $2,474,375 worth of shares (21,929 units at $112.84), increasing direct ownership by 20% to 130,149 units (SEC Form 4)

    4 - ICU MEDICAL INC/DE (0000883984) (Issuer)

    8/14/25 7:07:45 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    VP, General Counsel Sanzone Virginia Ruth sold $93,537 worth of shares (700 units at $133.62), decreasing direct ownership by 10% to 6,386 units (SEC Form 4)

    4 - ICU MEDICAL INC/DE (0000883984) (Issuer)

    5/30/25 2:34:28 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Voigtlander Christian B. exercised 11,115 shares at a strike of $96.83 and sold $1,288,371 worth of shares (9,930 units at $129.75), increasing direct ownership by 24% to 6,088 units (SEC Form 4)

    4 - ICU MEDICAL INC/DE (0000883984) (Issuer)

    5/28/25 12:00:55 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    $ICUI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER issued to ICU MEDICAL INC

    Submission status for ICU MEDICAL INC's drug POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (SUPPL-8) with active ingredient POTASSIUM CHLORIDE; SODIUM CHLORIDE has changed to 'Approval' on 05/15/2023. Application Category: ANDA, Application Number: 078446, Application Classification: Labeling

    5/17/23 4:40:03 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    $ICUI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on ICU Medical with a new price target

    Piper Sandler initiated coverage of ICU Medical with a rating of Overweight and set a new price target of $145.00

    8/15/25 8:19:19 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    ICU Medical upgraded by Raymond James with a new price target

    Raymond James upgraded ICU Medical from Outperform to Strong Buy and set a new price target of $197.00 from $205.00 previously

    3/12/25 7:28:15 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    ICU Medical upgraded by Jefferies with a new price target

    Jefferies upgraded ICU Medical from Hold to Buy and set a new price target of $200.00

    12/11/24 7:52:44 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    $ICUI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ICU Medical to Participate in Upcoming Investor Conferences

    SAN CLEMENTE, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- ICU Medical (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the following investor conferences in September: Wells Fargo 2025 Healthcare Conference on September 4, 2025 Company management will participate in a fireside chat at the Wells Fargo 2025 Healthcare Conference in Boston on Thursday, September 4, 2025. The discussion will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be webcast live on the Event Calendar section of the Company's Investor Relations website at https://ir.icumed.com. A replay of the webcast will be archived on the website for

    8/21/25 8:30:00 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    ICU Medical Announces Second Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance

    SAN CLEMENTE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2025. Second Quarter 2025 Results Second quarter 2025 revenue was $548.9 million, as compared to $596.5 million in the same period in the prior year. GAAP gross profit for the second quarter of 2025 was $208.1 million, as compared to $207.4 million in the same period in the prior year. GAAP gross margin for the second quarter of 2025 was 38%, as compared to 35% in the same period in the prior year. GAAP net income for the second quarter of 202

    8/7/25 4:05:00 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    ICU Medical Announces Time of Second Quarter 2025 Earnings Conference Call

    SAN CLEMENTE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2025 earnings release and conference call. The Company will release its second quarter 2025 results on Thursday, August 7, 2025 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, August 7, 2025. The call can be accessed at (800) 267-6316, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's

    7/24/25 8:30:00 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    $ICUI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman and CEO Jain Vivek bought $2,474,375 worth of shares (21,929 units at $112.84), increasing direct ownership by 20% to 130,149 units (SEC Form 4)

    4 - ICU MEDICAL INC/DE (0000883984) (Issuer)

    8/14/25 7:07:45 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    $ICUI
    Leadership Updates

    Live Leadership Updates

    View All

    Carlyle Group and WP Carey Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

    NEW YORK, Nov. 27, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 effective prior to the open of trading on Thursday, November 30: Carlyle Group Inc. (NASD: CG) will replace ICU Medical Inc. (NASD: ICUI) in the S&P MidCap 400. ICU Medical will replace PacWest Bancorp (NASD: PACW) in the S&P SmallCap 600. Banc of California Inc. (NYSE:BANC) is acquiring PacWest Bancorp in a deal expected to be completed soon, pending final closing conditions. Post-merger, Banc of California will remain in the S&P SmallCap 600. ICU Medical is more representative of the small-cap market space.WP Carey Inc. (NYSE: WPC) will replace Worthingt

    11/27/23 6:28:00 PM ET
    $AVTA
    $BANC
    $CG
    Finance: Consumer Services
    Finance
    Major Banks
    Investment Managers

    $ICUI
    Financials

    Live finance-specific insights

    View All

    ICU Medical Announces Second Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance

    SAN CLEMENTE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2025. Second Quarter 2025 Results Second quarter 2025 revenue was $548.9 million, as compared to $596.5 million in the same period in the prior year. GAAP gross profit for the second quarter of 2025 was $208.1 million, as compared to $207.4 million in the same period in the prior year. GAAP gross margin for the second quarter of 2025 was 38%, as compared to 35% in the same period in the prior year. GAAP net income for the second quarter of 202

    8/7/25 4:05:00 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    ICU Medical Announces Time of Second Quarter 2025 Earnings Conference Call

    SAN CLEMENTE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2025 earnings release and conference call. The Company will release its second quarter 2025 results on Thursday, August 7, 2025 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, August 7, 2025. The call can be accessed at (800) 267-6316, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's

    7/24/25 8:30:00 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    ICU Medical Announces First Quarter 2025 Results

    SAN CLEMENTE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2025. First Quarter 2025 Results First quarter 2025 revenue was $604.7 million, as compared to $566.7 million in the same period in the prior year. GAAP gross profit for the first quarter of 2025 was $210.1 million, as compared to $185.2 million in the same period in the prior year. GAAP gross margin for the first quarter of 2025 was 35%, as compared to 33% in the same period in the prior year. GAAP net loss for the first quarter of 2025 was $(15.

    5/8/25 4:05:00 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    $ICUI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ICU Medical Inc.

    SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)

    11/12/24 3:44:43 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ICU Medical Inc.

    SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)

    11/8/24 10:34:33 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by ICU Medical Inc.

    SC 13D/A - ICU MEDICAL INC/DE (0000883984) (Subject)

    7/18/24 7:06:07 AM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    $ICUI
    SEC Filings

    View All

    SEC Form S-8 filed by ICU Medical Inc.

    S-8 - ICU MEDICAL INC/DE (0000883984) (Filer)

    8/8/25 4:05:53 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by ICU Medical Inc.

    10-Q - ICU MEDICAL INC/DE (0000883984) (Filer)

    8/7/25 4:17:58 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care

    ICU Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ICU MEDICAL INC/DE (0000883984) (Filer)

    8/7/25 4:11:06 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care